Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial.
Aged
Drug Administration Schedule
Endothelium, Vascular
/ drug effects
Female
Follow-Up Studies
Humans
Male
Middle Aged
Netherlands
Platelet Activation
/ drug effects
Platelet Aggregation Inhibitors
/ therapeutic use
Platelet Function Tests
Prasugrel Hydrochloride
/ therapeutic use
ST Elevation Myocardial Infarction
/ drug therapy
Spain
Ticagrelor
/ therapeutic use
Time Factors
Treatment Outcome
ST‐segment‐elevation myocardial infarction
endothelial function
microvascular injury
platelet inhibition
prasugrel
ticagrelor
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
03 03 2020
03 03 2020
Historique:
entrez:
4
3
2020
pubmed:
4
3
2020
medline:
18
3
2021
Statut:
ppublish
Résumé
Background Off-target properties of ticagrelor might reduce microvascular injury and improve clinical outcome in patients with ST-segment-elevation myocardial infarction. The REDUCE-MVI (Evaluation of Microvascular Injury in Revascularized Patients with ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel) trial reported no benefit of ticagrelor regarding microvascular function at 1 month. We now present the follow-up data up to 1.5 years. Methods and Results We randomized 110 patients with ST-segment-elevation myocardial infarction to either ticagrelor 90 mg twice daily or prasugrel 10 mg once a day. Platelet inhibition and peripheral endothelial function measurements including calculation of the reactive hyperemia index and clinical follow-up were obtained up to 1.5 years. Major adverse clinical events and bleedings were scored. An intention to treat and a per-protocol analysis were performed. There were no between-group differences in platelet inhibition and endothelial function. At 1 year the reactive hyperemia index in the ticagrelor group was 0.66±0.26 versus 0.61±0.28 in the prasugrel group (
Identifiants
pubmed: 32122216
doi: 10.1161/JAHA.119.014411
pmc: PMC7335553
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Banques de données
ClinicalTrials.gov
['NCT02422888']
Types de publication
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e014411Commentaires et corrections
Type : CommentIn
Références
N Engl J Med. 2019 Oct 17;381(16):1524-1534
pubmed: 31475799
Circulation. 2016 Sep 13;134(11):780-92
pubmed: 27559041
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Circulation. 2019 Jan 29;139(5):636-646
pubmed: 30586720
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586
pubmed: 29805112
N Engl J Med. 2009 Sep 10;361(11):1108-11
pubmed: 19717845
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1646-1658
pubmed: 28838475
Biochem Biophys Res Commun. 2012 Feb 24;418(4):754-8
pubmed: 22306816
J Cardiovasc Transl Res. 2016 Jun;9(3):249-256
pubmed: 27102290
J Thromb Haemost. 2013 Oct;11(10):1867-76
pubmed: 23890048
Circ Cardiovasc Interv. 2012 Dec;5(6):797-804
pubmed: 23169985
J Am Coll Cardiol. 2011 Jun 21;57(25):2474-83
pubmed: 21679849
Kardiol Pol. 2018;76(12):1585-1664
pubmed: 30566213
Purinergic Signal. 2008 Mar;4(1):1-20
pubmed: 18368530
J Pharmacol Exp Ther. 1998 Mar;284(3):1066-73
pubmed: 9495868
Atherosclerosis. 2013 Dec;231(2):392-400
pubmed: 24267257
J Am Coll Cardiol. 2003 May 21;41(10):1761-8
pubmed: 12767662
Lancet. 2013 Aug 17;382(9892):614-23
pubmed: 23890998
J Thromb Thrombolysis. 2012 Apr;33(3):267-73
pubmed: 22362558
J Am Coll Cardiol. 2007 Nov 6;50(19):1852-6
pubmed: 17980251
Eur Heart J. 2011 Dec;32(23):2945-53
pubmed: 21804104
Circulation. 2003 Jun 17;107(23):2908-13
pubmed: 12796140
Circulation. 2016 Nov 22;134(21):1603-1612
pubmed: 27576777
J Am Coll Cardiol. 1995 Nov 1;26(5):1235-41
pubmed: 7594037
J Am Coll Cardiol. 2014 Mar 11;63(9):872-7
pubmed: 24291273
J Thromb Thrombolysis. 2015 Jan;39(1):1-7
pubmed: 25085573
Cardiology. 2013;124(4):252-8
pubmed: 23594617
Heart. 2018 Jan;104(2):127-134
pubmed: 28663361
J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209-19
pubmed: 24414167
J Am Heart Assoc. 2020 Mar 3;9(5):e014411
pubmed: 32122216
N Engl J Med. 2007 Nov 15;357(20):2001-15
pubmed: 17982182
Eur Heart J. 2015 Jul 14;36(27):1762-71
pubmed: 25896078
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537
pubmed: 31202949
Circulation. 2003 Feb 25;107(7):1040-5
pubmed: 12600919
J Am Coll Cardiol. 2004 Dec 7;44(11):2137-41
pubmed: 15582310
N Engl J Med. 2010 Mar 11;362(10):886-95
pubmed: 20220183
J Cardiovasc Pharmacol. 2018 Oct;72(4):186-190
pubmed: 29985284
J Am Coll Cardiol. 2013 Feb 19;61(7):723-7
pubmed: 23312702
J Am Coll Cardiol. 2014 Jun 17;63(23):2503-2509
pubmed: 24768873
Circulation. 2000 Feb 29;101(8):841-3
pubmed: 10694520
Circ Cardiovasc Interv. 2015 Mar;8(3):e001786
pubmed: 25717044
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Am J Cardiol. 2015 Mar 15;115(6):716-23
pubmed: 25728845
J Am Coll Cardiol. 2011 Jul 26;58(5):467-73
pubmed: 21777742
Int J Cardiol. 2013 Sep 1;167(5):1877-81
pubmed: 22682702
J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73
pubmed: 24076493
Eur Heart J. 2015 Dec 1;36(45):3202-10
pubmed: 26216931
J Am Heart Assoc. 2013 Nov 25;2(6):e000426
pubmed: 24275629
J Am Coll Cardiol. 2010 Jul 13;56(3):185-93
pubmed: 20620737